Article info

Download PDFPDF

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Authors

  1. a stefanie.mullins{at}astrazeneca.com
  2. s wilkinsonr{at}medimmune.com
View Full Text

Citation

Mullins SR, Vasilakos JP, Deschler K, et al
Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Publication history

  • Received April 1, 2019
  • Accepted August 28, 2019
  • First published September 11, 2019.
Online issue publication 
September 11, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.